Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support

Journal of Oncology Pharmacy Practice

Volumn 16, Issue 1, 2010, Pages 45-51

  Paul, Betsy ^a   Trovato, James A ^b   Thompson, Jennifer ^c   Badros, Ashraf Z ^d   Goloubeva, Olga ^c  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; DEXAMETHASONE; DOLASETRON MESILATE; ONDANSETRON;

ABDOMINAL PAIN; ADULT; ALCOHOL CONSUMPTION; ANAMNESIS; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HICCUP; HOT FLUSH; HUMAN; MALE; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; PRIORITY JOURNAL; RASH; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HICCUP; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SLEEP STAGES; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 77749298960     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155209105399     Document Type: Article

References (12)

1. Bender C., McDaniel R., Murphy-Ende K., Pickett M., Rittenberg CN, Rogers MP et al. Chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing 2002 ; 6: 94-102.
2. Schnell F. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. The Oncologist 2003 ; 8: 187-198.
3. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F., de Wit R. et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double blind, placebo-controlled trial in patients receiving high-dose cisplatin. Analysis of Combined Data from Two Phase III Randomized Clinical Trials. Cancer 2005 ; 104 (4). 864-868.
4. Gralla RJ, de Wit R., Herrstedt J., Carides AD, Ianus J., Guoguang-Ma J. et al. Antiemetic efficacy of neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin. Analysis of combined data from two phase III randomized clinical trials. Cancer 2005 ; 104 (4). 864-868.
5. De Wit R., Herrstedt J., Rapoport B., Carides AD, Carides G., Elmer M. et al. Addition of oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Journal of Clinical Oncology 2003 ; 21 (22). 4105-4111.
6. Kris MG, Hesketh PJ, Somerfield MR, Feyer P., Clark-Snow R., Koeller JM et al. American society of clinical oncology guideline for antiemetics in oncology: Update 2006. Journal of Clinical Oncology 2006 ; 24 (18). 1-16.
7. Roila F., Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international consensus conference. Annals of Oncology 2006 ; 17: 20-28.
8. Antiemesis. National Comprehensive Cancer Network. 2006: April: Version 2.
9. Yen CC, Hsieh RK, Chiou TJ, Liu JH, Fang FS, Wang WS et al. Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation. Japanese Journal of Clinical Oncology 1998 ; 28 (2). 129-133.
10. Hesketh P., Ballen K., Hesketh A., LeFebvre K., Heyes C., Fogarty K. et al. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Abstract No. 2387. American Society of Clinical Oncology 2000 ; Abs No. 2387.
11. Abbott B., Ippoliti C., Hecth D., Bruton J., Whaley B., Champlin R. et al. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplantation 2000 ; 25: 1279-1283.
12. Clinical Trials.gov (Available at http://www.clinicaltrials.gov/ct2/show/ NCT00314743?term=emend&rank=35 last accessed on 7/25/2008).